Morphogenesis and Lacerta Named as Finalists for SEBIO Awards

Morphogenesis and Lacerta Named as Finalists for SEBIO Awards (SEBIO)

Two UF startups who have incubated at UF Innovate | Sid Martin Biotech have been named as finalists for the SEBIO awards. Sid Martin alum Morphogenesis is a finalist in Initial Venture Funding; Sid Martin resident client Lacerta Therapeutics is a finalist in the Strategic Investment category.

Over the past two decades, the Southeast has seen an increasing number of startups and venture capital investments. This maturation of the regional startup ecosystem has been
spurred by an increase in notable exits and an increased focus and commitment from universities, state legislatures, local government and local financiers.

Annually, SEBIO recognizes best in class deals by the region’s biomedical companies in five categories: Public Offering, Strategic Acquisition, Strategic Investment, Venture Funding and Initial Venture Funding. The winners of the 2018 SEBIO awards will be announced at the 20th Annual SEBIO conference on November 14.

Learn more about Morphogenesis and Lacerta Named as Finalists for SEBIO Awards.

X